The Role Of Glutamate In Mood Disorders & Schizophrenia

Tuesday, March 19, 2019 | 12pm ET | 9am PT

Glutamate is the predominant excitatory neurotransmitter in the nervous system, and glutamatergic dysregulation has been implicated in the pathophysiology of both mood disorders and schizophrenia.

In this webinar, James Murrough, MD, PhD, and Laura Rowland, PhD, will examine current research in this area, provide an overview of ionotropic and metabotropic glutamate receptors, discuss the rationale for development of glutamatergic modulators in the treatment of mood disorders and schizophrenia, and review various targets for therapy.

Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.

James Murrough, MD, PhD
Associate Professor, Psychiatry and Neuroscience, and Director, Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine, Mount Sinai

Laura Rowland, PhD
Associate Professor, Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine

Gerard Zitnik, PhD
Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. will be the moderator of this event.